*February 2021*
Click here to read the EGFR Resisters Research Newsletter and learn more about the Summit and the prize winners. These young investigators describe how the Summit impacted them and how they will spend their grants.
We are a group of lung cancer patients with EGFR mutations who have developed resistance to at least one targeted treatment drug, or who face probable resistance in the future. Caregivers are also welcome. We are here to share treatment experiences, information about clinical trials, breaking news about research developments, and other information with each other.